MARKET

CVM

CVM

CEL SCI
AMEX

Real-time Quotes | Nasdaq Last Sale

12.00
+0.08
+0.67%
Closed 16:00 12/04 EST
OPEN
12.01
PREV CLOSE
11.92
HIGH
12.11
LOW
11.76
VOLUME
284.98K
TURNOVER
--
52 WEEK HIGH
18.00
52 WEEK LOW
6.35
MARKET CAP
464.83M
P/E (TTM)
-14.6520
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Where Do Hedge Funds Stand On CEL-SCI Corporation (CVM)?
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the third quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
Insider Monkey · 2d ago
CEL-SCIs LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies
CEL-SCI’s LEAPS Peptides Demonstrate Clear Survival Benefit as a Treatment for COVID-19 in Preclinical Studies.
Business Wire · 3d ago
CEL-SCI Corporation's (NYSEMKT:CVM) Shift From Loss To Profit
We feel now is a pretty good time to analyse CEL-SCI Corporation's (NYSEMKT:CVM) business as it appears the company...
Simply Wall St. · 10/14 12:19
CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis
CEL-SCI awarded European patent for LEAPS Vaccine in treatment of Rheumatoid Arthritis.
Business Wire · 09/18 14:00
CEL-SCI nabs European patent covering LEAPS vaccine for rheumatoid arthritis
The European Patent Office has issued patent to CEL-SCI (CVM) titled “Method of Preparation and Composition of Peptide Constructs for Treatment of Rheumatoid Arthritis” for the Company’s LEAPS platform technology.We are
Seekingalpha · 09/18 13:20
CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis
CEL-SCI Corporation (NYSE American: CVM) today announced that the European Patent Office has issued CEL-SCI patent: European Patent 2989121 to be published on October 7, 2020, and titled "Method of Preparation and Composition of Peptide Constructs for Treatment of Rheumatoid Arthritis" for the Company's LEAPS platform technology. CEL-SCI's LEAPS technology relates to peptide constructs which may be useful in the treatment or prevention of autoimmune diseases, particularly rheumatoid arthritis, asthma, allergies, and host versus graft (or graft versus host) rejection.
BusinessWire · 09/18 13:00
CEL-SCI Corporation Issues Letter to Shareholders
Business Wire · 09/15 14:15
CEL-SCI Corporation Issues Letter to Shareholders
CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders.
BusinessWire · 09/15 13:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CVM. Analyze the recent business situations of CEL SCI through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CVM stock price target is 23.00 with a high estimate of 23.00 and a low estimate of 23.00.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 5.85M
% Owned: 15.10%
Shares Outstanding: 38.74M
TypeInstitutionsShares
Increased
19
2.66M
New
30
493.48K
Decreased
4
177.55K
Sold Out
3
243.82K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.20%
Pharmaceuticals & Medical Research
+1.62%
Key Executives
Chief Executive Officer/Director/Treasurer
Geert Kersten
Senior Vice President/Secretary
Patricia Prichep
Senior Vice President
John Cipriano
Senior Vice President
Daniel Zimmerman
Chief Scientific Officer
Eyal Talor
Independent Director
Bruno Baillavoine
Independent Director
Robert Watson
Independent Director
Peter Young
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CVM
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The Company is focused on activating the immune system to fight cancer and infectious diseases. It operates through the segment of research and development of certain drugs and vaccines. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for treatment of certain head and neck cancers, and anal warts or cervical dysplasia in human immunodeficiency virus and human papillomavirus co-infected patients and Ligand Epitope Antigen Presentation System (L.E.A.P.S.) technology, with over two investigational therapies, LEAPS-H1N1-DC, a product candidate under development for treatment of pandemic influenza in hospitalized patients, and CEL-2000 and CEL-4000, vaccine product candidates under development for treatment of rheumatoid arthritis.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of CEL-SCI Corporation stock information, including AMEX:CVM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CVM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CVM stock methods without spending real money on the virtual paper trading platform.